FDA reviewers, inspectors, and investigators excluded from $25K buyout offer

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesGovernment/legislationMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)